Study reveals optimal treatment for most common infection after organ transplantation

Waiting to treat the commonest viral infections in transplant recipients until they reach a certain threshold is better than prophylactically treating all recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Cytomegalovirus (CMV) infection is the most common infection in , who are susceptible to infections in general because they must take immunosuppressive medications long term. CMV infections can cause increased risks of other infections, , , and diabetes.

The two main strategies against CMV are called universal antiviral prophylaxis and pre-emptive therapy. In universal prophylaxis all patients at risk are given (such as , valacyclovir, and ganciclovir) for several months after transplantation. In pre-emptive therapy, patients are intensively monitored for CMV activity by sensitive laboratory methods, and short-term is given only to those with significant viral counts before symptoms occur.

To compare these strategies, Tomas Reischig, MD, PhD (Charles University Medical School and Teaching Hospital, in Pilsen, Czech Republic) and his colleagues assigned —who either had CMV present in their blood or who received transplants from donors with CMV in their blood—to either three months of prophylaxis with valacyclovir or pre-emptive valganciclovir given when significant CMV counts were detected.

Among the major findings for 55 patients after three years:

  • CMV disease developed in 6% of patients in the pre-emptive therapy group and in 9% receivin prophylaxis
  • Patients in the prophylaxis group were 2.5 times more likely to develop moderate-to-severe kidney scaring and atrophy than patients receiving pre-emptive therapy.
  • Kidney biopsies showed that the prophylaxis group also had significantly higher expression of genes involved in kidney scaring.
  • The occurrence of CMV was similar in both groups, but pre-emptive therapy improved 4-year survival of transplanted organs (92% vs 74%).

These findings indicate that compared with valacyclovir prophylaxis, pre-emptive valganciclovir therapy for CMV may lead to less severe kidney scaring and atrophy and to significantly better survival of transplanted organs.

"In the view of short-term trial results, which favor CMV prophylaxis over pre-emptive strategy because of lower risk of acute rejection, we expected a translation of presumed benefit of prophylaxis to the long-term post-transplant period. In fact, we discovered that the opposite is true," said Dr. Reischig.

More information: doi: 10.1681/ASN.2012010100

add to favorites email to friend print save as pdf

Related Stories

It pays to be careful post-kidney transplant

Sep 18, 2009

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney ...

Recommended for you

Is head CT overused in emergency departments?

4 hours ago

Less than 7.1% of patients presenting to the emergency department with dizziness and 6.4% complaining of syncope or near-syncope benefited from head CT say researchers at Kaiser Foundation Hospital in Honolulu. The use of ...

Medical radiation may be reduced to one-sixth

6 hours ago

One of this century's most significant mathematical discoveries may reduce the number of measuring points to one-sixth of the present level. This means reduced exposure to radiation and faster medical imaging ...

The 'fifth taste,' umami, could be beneficial for health

19 hours ago

The umami taste could have an important and beneficial role in health, according to research published in the open access journal Flavour. The journal's special series of articles 'The Science of Taste' also finds that ' ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.